DOCSLIB.ORG

Treatment Outcome of Radiotherapy for Localized Primary Ocular Adnexal MALT Lymphoma – Prognostic Effect of the AJCC Tumor-Node-Metastasis Clinical Staging System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treatment Outcome of Radiotherapy for Localized Primary Ocular Adnexal MALT Lymphoma – Prognostic Effect of the AJCC Tumor-Node-Metastasis Clinical Staging System ANTICANCER RESEARCH 35: 3591-3598 (2015) Treatment Outcome of Radiotherapy for Localized Primary Ocular Adnexal MALT Lymphoma – Prognostic Effect of the AJCC Tumor-Node-Metastasis Clinical Staging System SAIJI OHGA1, KATSUMASA NAKAMURA1, YOSHIYUKI SHIOYAMA2, TOMONARI SASAKI1, TOSHIHIRO YAMAGUCHI1, TADAMASA YOSHITAKE1, KOTARO TERASHIMA1, KAORI ASAI1, KEIJI MATSUMOTO1 and HIROSHI HONDA1 1Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 2Kyushu International Heavy Ion Beam Cancer Treatment Center, Saga, Japan Abstract. Aim: To analyze the treatment outcome of frequently treated by radiotherapy alone and radiotherapy can radiotherapy for localized primary ocular adnexal mucosa- achieve excellent local control (LC) (5). POAML affects the associated lymphoid tissue lymphoma (POAML) and evaluate conjunctivae, orbits, eyelids, lacrimal glands etc. The Ann the prognostic effect of the American Joint Committee on Arbor staging system has been widely applied for staging of Cancer (AJCC) tumor-node-metastasis (TNM) clinical staging POAML (6, 7). However, in the Ann Arbor staging system, system for POAML. Patients and Methods: Seventy-three ocular adnexal tumors without other lesions are categorized as patients with Ann Arbor stage IE POAML who were treated stage IE, irrespective of their location. Bilateral ocular adnexal with radiotherapy alone were analyzed. T-Factor based on the lesions are also classified into stage IE by the Ann Arbor AJCC staging system was T1 in 28, T2 in 33 and T3 in 12 system. Several investigators have reported that the specific patients. Results: Out of nine patients with relapse, six had disease locations of ocular adnexal lymphoma were associated distant and three had contralateral ocular adnexal relapse. with their prognosis (8-11). For example, poor prognosis was One patient died of lymphoma progression. The 5-year local reported for MALT lymphoma in the eyelid or orbit with control and progression-free survival (PFS) rates were 100% lacrimal gland involvement, lymphomatous involvement of the and 81.5%, respectively. T-Factor was not significantly extraocular muscle and mass-forming type (8-10). In short, the associated with PFS. Conclusion: Radiotherapy achieved Ann Arbor staging system does not precisely define the disease excellent local control and survival rates for stage IE POAML. extent or site-specific prognosis of localized primary ocular The AJCC TNM clinical staging system was not significantly adnexal lymphoma. There is thus a need for a staging system predictive for PFS of stage IE POAML. that can provide prognostic information for the treatment of POAML. More recently, a tumor-node-metastasis (TNM)- Most cases of primary ocular adnexal lymphoma are extranodal based clinical staging system for primary ocular adnexal marginal zone lymphomas of the mucosa-associated lymphoid lymphoma was developed under the guidance of the American tissue (MALT) type (1-3). MALT lymphoma was first Joint Committee on Cancer (AJCC). This staging system presented in 1983 by Isaacson et al. (4). This disease is addresses many of the shortcomings of the Ann Arbor system categorized as a low-grade lymphoma due to its slow and more precisely defines the disease extent (11, 12). progression. Because MALT lymphoma rarely metastasizes to To date, there have been few reports analyzing the distant sites and is sensitive to radiation in general, localized feasibility of the AJCC TNM clinical staging system for primary ocular adnexal MALT lymphoma (POAML) is patients with Ann Arbor stage IE POAML who were treated by radiotherapy alone. In the present study, we analyzed the treatment outcome of radiotherapy for POAML and evaluated the prognostic effect of the AJCC TNM clinical Correspondence to: Saiji Ohga, Department of Clinical Radiology, staging system for Ann Arbor stage IE POAML. Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Tel: +81 926425695, Fax: +81 926425708, e-mail: [email protected] Patients and Methods Key Words: Primary ocular adnexal MALT lymphoma, AJCC TNM Patients’ characteristics. From 1997 to 2012, 92 patients with clinical staging system, radiotherapy. POAML were treated with radiotherapy alone at our Hospital. 0250-7005/2015 $2.00+.40 3591 ANTICANCER RESEARCH 35: 3591-3598 (2015) Eighteen patients with short follow-up and one patient with stage Table I. Patient characteristics. IIE disease based on the Ann Arbor staging system were excluded from this study. The remaining 73 patients with Ann Arbor stage IE Characteristic Range (Median) n POAML were analyzed. The median patient age was 63 years (range=22 to 90 years). Performance status (PS) was 0 in 41 and 1 Age 22-90 (63) in 32 patients according to the Eastern Cooperative Oncology Group >60/<60 years 43/30 (ECOG) criteria (13). In this study, tumors were divided into two Gender categories by their morphology: superficial (SF) type and mass- Male/female 31/42 forming (MF) type. SF-type tumors were defined as invisible on PS 0/1 41/32 computed tomographic images, and MF-type tumors were defined Tumor type as visible on computed tomographic images. Twelve patients had Superficial/mass-forming 12/61 SF-type tumor and the others had MF-type tumor. The Ann Arbor Stage* stage IE tumors of all 73 patients were assessed by the AJCC TNM I73 clinical staging system. In the AJCC TNM staging system, the T- T stage# factor of primary ocular adnexal tumors is used to divide them by T1/T2/T3 30/31/12 anatomic location and tumor extent. T1 tumors are defined as conjunctival lesions and T2 as orbital lesions, irrespective of PS: Performance status; *according to the Ann Arbor staging system; whether or not the conjunctiva is affected. T3 tumors are considered #according to the American Joint Committee on Cancer tumor-node- lymphoma with preseptal eyelid involvement. Finally, T4 tumors are metastasis staging system for ocular adnexal lymphoma. classified as orbital adnexal lymphomas extending beyond the orbit to adjacent structures. By the AJCC TNM staging system, our patient group included 28, 33 and 12 patients with T1, T2 and T3 disease, respectively (Table I). The median time to relapse was 43 months. Out of these Treatment. The gross tumor volume (GTV) included the tumor extent. nine patients, six had distant relapse and three had The entire anatomical region involved by the tumor was delineated as contralateral ocular adnexal relapse (Table II). The relapse the clinical target volume (CTV). For example, the CTVs of T1 and sites of the six patients with distant relapse were the T2 lesions were the conjunctiva and orbita, respectively. The PTV mesenterium, kidney, neck lymph nodes, tonsils, inguinum included the CTV with a 10 mm to 15 mm margin. Patients with POAML were treated with involved-field radiotherapy. The field did and multiple lymph nodes. Three out of these six patients not include the regional lymphatic area. In this study, lens shielding were able to achieve a complete response (CR) by and lacrimal gland shielding were performed, provided the shielding combined treatment with chemotherapy and local did not reduce the dosage to the tumor. Lens shielding was performed radiotherapy. Two patients achieved a CR by chemotherapy in 11 patients. Lacrimal gland shielding was performed in eight alone. However, one patient experienced further relapse patients. The radiation dose was 24 Gy in 12 fractions for SF lesions, after a second CR. At the third relapse, she underwent a and 30 Gy in 20 fractions for MF lesions, with the exception of a biopsy of recurrent perirenal tumor. Pathological analysis single case treated with 18 Gy in 12 fractions. Thus the dose delivered ranged from 18 to 30 Gy (median=30 Gy). confirmed that the tumor was diffuse large B-cell lymphoma. Although this patient underwent chemotherapy Response. The initial response was evaluated according to the following peripheral blood stem cell implantation, she died Cheson criteria at 3 months after the radiotherapy (14). The time to of progression of lymphoma at 135 months after the start local and distant relapse was measured from the start of of treatment. One patient with multiple lymph node relapse radiotherapy. Acute and late adverse events were evaluated received treatment at another hospital, therefore the according to the Common Terminology Criteria for Adverse Events, treatment response was unknown. In all three patients with version 4.0 (CTCAE v.4.0) (15). contralateral ocular adnexal relapse, the conjunctivae were Statistical analysis. Progression-free survival (PFS) and overall the primary site. The conjunctivae were also the survival (OS) were calculated from the start of radiotherapy using contralateral relapse sites. Among these three patients, one the Kaplan–Meier method. Predictive factors for PFS and the achieved CR by local radiotherapy for the relapsed site. difference in PFS between two T-factor groups were evaluated using The others were observed without additional treatment due the log-rank test. The predictive factors for PFS analyzed included to slow growth of tumor. One patient died of lung cancer the age, gender, PS, tumor type, radiation dose and initial response at 94 months after the start of treatment. of patients. The associations between late adverse events and shielding were examined using Fisher’s exact test. A p-value of less The 5-year PFS and OS rates were 81.5% and 100%, than 0.05 was considered statistically significant. respectively (Figure 1). Age, gender, PS, morphological tumor type, radiation dose and initial response of patients did Results not significantly associate with PFS (Table III). PFS by T- factor was 62.9% in T1, 85.4% in T2 and 100% in T3 The median duration of follow-up was 45 months. The 5- patients. The T-factor was also not significantly associated year LC rate was 100%. Nine patients experienced relapse. with PFS (Table IV). 3592 Ohga et al: Treatment Outcome of Radiotherapy for Localized Primary Ocular Adnexal MALT Lymphoma Figure 1.
Load more

Recommended publications
  • Childhood Cancer Staging for Population Registries
    Childhood cancer staging for population registries according to the 1 Toronto Childhood Cancer Stage Guidelines Acknowledgements This project was funded by Cancer Australia through an initiative to strengthen national data capacity for reporting cancer stage at diagnosis. We also acknowledge and thank the Australasian Association of Cancer Registries, all Australian State and Territory Cancer Registries, the Australian Institute of Health and Welfare and the treating hospitals listed below for their support of the Australian Childhood Cancer Registry and of this project: Lady Cilento Children’s Hospital, Brisbane Sydney Children’s Hospital, Sydney The Children’s Hospital at Westmead, Sydney John Hunter Hospital, Newcastle Royal Children’s Hospital, Melbourne Monash Medical Centre, Melbourne The Women’s and Children’s Hospital, Adelaide Princess Margaret Hospital for Children, Perth Royal Hobart Hospital, Hobart Suggested citation Aitken JF, Youlden DR, Moore AS, Baade PD, Ward LJ, Thursfield VJ, Valery PC, Green AC, Gupta S, Frazier AL. Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2017. Available at https://cancerqld.blob.core.windows.net/content/docs/childhood-cancer-staging-for- population-registries.pdf. Childhood cancer staging for population registries – November 2017 2 Table of contents Acknowledgements ........................................................................................................................................
    [Show full text]
  • Seer Research Data Record Description 2019
    SEER RESEARCH DATA RECORD DESCRIPTION CASES DIAGNOSED IN 1975-2016* Submission: November 2018 Follow-up Cutoff Date: December 31, 2016 Documentation Version: April 2019 Diagnosis Years: 1975-2016 * This documentation describes the data files in the incidence/yr1975_2016.seer9, yr1992_2016.sj_lx_rg_ak, yr2000_2016.gc_ky_la_nj_gg , and yr2005.la_2nd_half directories. Refer to individual variable definitions to determine the differences between the directory files. Starting with November 2017 submission, all cervix in situ cases have been removed. In prior submissions, cervix in situ cases were included for 1975-1995 diagnoses Starting with November 2018 submission, all 1973-1974 diagnosed cases have been removed. 2 SEER Research Data Record Description April 2019 TABLE OF CONTENTS PATIENT ID NUMBER ........................................................................................................... 10 REGISTRY ID .......................................................................................................................... 10 MARITAL STATUS AT DX..................................................................................................... 11 RACE / ETHNICITY ................................................................................................................ 12 SEX .......................................................................................................................................... 13 AGE AT DIAGNOSIS .............................................................................................................
    [Show full text]
  • Paediatric Cancer Stage in Population-Based Cancer Registries: the Toronto Consensus Principles and Guidelines
    Review Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines Sumit Gupta, Joanne F Aitken, Ute Bartels, James Brierley, Mae Dolendo, Paola Friedrich, Soad Fuentes-Alabi, Claudia P Garrido, Gemma Gatta, Mary Gospodarowicz, Thomas Gross, Scott C Howard, Elizabeth Molyneux, Florencia Moreno, Jason D Pole, Kathy Pritchard-Jones, Oscar Ramirez, Lynn A G Ries, Carlos Rodriguez-Galindo, Hee Young Shin, Eva Steliarova-Foucher, Lillian Sung, Eddy Supriyadi, Rajaraman Swaminathan, Julie Torode, Tushar Vora, Tezer Kutluk, A Lindsay Frazier Population-based cancer registries generate estimates of incidence and survival that are essential for cancer Lancet Oncol 2016; 17: e163–72 surveillance, research, and control strategies. Although data on cancer stage allow meaningful assessments of Division of Haematology/ changes in cancer incidence and outcomes, stage is not recorded by most population-based cancer registries. Oncology, Hospital for Sick The main method of staging adult cancers is the TNM classifi cation. The criteria for staging paediatric cancers, Children, Toronto, ON, Canada (S Gupta PhD, U Bartels MD, however, vary by diagnosis, have evolved over time, and sometimes vary by cooperative trial group. Consistency in the L Sung PhD); Department of collection of staging data has therefore been challenging for population-based cancer registries. We assembled key Paediatrics, Faculty of experts and stakeholders (oncologists, cancer registrars, epidemiologists) and used a modifi ed Delphi approach to Medicine, University of establish principles for paediatric cancer stage collection. In this Review, we make recommendations on which Toronto, Toronto, ON, Canada (S Gupta, U Bartels, L Sung); staging systems should be adopted by population-based cancer registries for the major childhood cancers, including Cancer Council Queensland, adaptations for low-income countries.
    [Show full text]
  • Lugano Recommendations
    VOLUME 32 ⅐ NUMBER 27 ⅐ SEPTEMBER 20 2014 JOURNAL OF CLINICAL ONCOLOGY SPECIAL ARTICLE Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington, Franco Cavalli, Lawrence H. Schwartz, Emanuele Zucca, and T. Andrew Lister Bruce D. Cheson, Georgetown Univer- See accompanying article on page 3048 sity Hospital, Lombardi Comprehensive Cancer Center, Washington, DC; Rich- ard I. Fisher, Fox Chase Cancer Center, ABSTRACT Philadelphia, PA; Sally F. Barrington, St Thomas’ Hospital; T. Andrew Lister, St Abstract Bartholomew’s Hospital, London, The purpose of this work was to modernize recommendations for evaluation, staging, and response United Kingdom; Franco Cavalli and assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). A workshop Emanuele Zucca, Oncology Institute of was held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, in Southern Switzerland, Bellinzona, Swit- June 2011, that included leading hematologists, oncologists, radiation oncologists, pathologists, zerland; and Lawrence H. Schwartz, radiologists, and nuclear medicine physicians, representing major international lymphoma clinical trials Columbia University, New York, NY. groups and cancer centers. Clinical and imaging subcommittees presented their conclusions at a Published online ahead of print at subsequent workshop at the 12th International Conference on Malignant Lymphoma, leading to www.jco.org on August 11, 2014. revised criteria for staging and of the International Working Group Guidelines of 2007 for response. Processed as a Rapid Communication As a result, fluorodeoxyglucose (FDG) positron emission tomography (PET)–computed tomogra- manuscript. phy (CT) was formally incorporated into standard staging for FDG-avid lymphomas.
    [Show full text]
  • Current Issues in Cancer
    Current Issues in Cancer Non-Hodgkin's lymphoma-. I: characterisation and treatment BMJ: first published as 10.1136/bmj.304.6843.1682 on 27 June 1992. Downloaded from Susan E O'Reilly, Joseph M Connors This is the eighth in a series of The non-Hodgkin's lymphomas are a heterogeneous providing increasing insight into the molecular artic es examining recent collection of lymphoproliferative malignancies whose biological origin of lymphomas and have shown that developments in cancer clinical behaviour, prognosis, and management vary the follicular (nodular) lymphomas are almost exclu- widely according to histological subtype, stage, and sively ofB cell origin and that lymphoblastic lymphoma bulk of disease. They are the seventh most commonly and mycosis fungoides typically arise from T cells. diagnosed malignancy. Typically patients present with Diffuse lymphomas may arise from B or T cells or may localised or generalised lymphadenopathy. Common be of indeterminate origin. We have used the working presenting findings are haematological cytopenias, formulation terminology throughout this review (table drenching night sweats, unexplained fevers, or weight I). loss greater than 10% of baseline (B symptoms); Developmentsinimmunology, monoclonal antibody hepatosplenomegaly, abdominal masses, or compres- probes, cytogenetics, and characterisation ofoncogenes sion of internal organs such as the gastrointestinal and growth factors will continue to expand our under- tract, blood vessels, airways, spinal cord, ureters, or standing of lymphomas. And these added insights into bile ducts; or localised tumours of parenchymal or lymphoma classification may eventually translate into visceral organs. Nevertheless, lymphoma may mimic improved treatments. Nevertheless, despite the virtually any other neoplasm. increasing sophistication of the molecular biologists Until about 25 years ago, most patients with non- and pathologists most clinical decisions are based on Hodgkin's lymphomas died of their disease.
    [Show full text]
  • Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients With
    102 Erciyes Med J 2015; 37(3): 102-5 • DOI: 10.5152/etd.2015.150001 Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma ORIGINAL INVESTIGATION Erol Çakmak1, İsmail Sarı2, Özlem Canoz3, Bülent Eser4, Fevzi Altuntaş5, Mustafa Çetin4, Ali Ünal4 ABSTRACT Objective: P53, Bcl-2, and Fas proteins play significant roles in lymphoid cell apoptosis. These proteins affect the prognosis and treatment response of lymphoma and various malignancies. The aim of the present study was to investigate the effects of P53, Bcl-2, and Fas protein expression on treatment and prognosis in patients with primary gastrointestinal diffuse large B-cell lymphoma. Materials and Methods: Thirty-nine patients with primary gastrointestinal diffuse large B-cell lymphoma were included in the study. Immunohistochemical staining was performed to analyze P53, Bcl-2, and Fas protein expression levels in paraffin sections. Results: We examined 39 patients with primary gastrointestinal diffuse large B-cell lymphoma, 21 males and 18 females, with a median age of 54 years. P53 protein expression was detected in 24 patients (61.5%), Bcl-2 protein expression was detected in 26 (67%), and Fas protein expression was detected in 28 (72%). The five-year overall survival rate was significantly lower in patients with P53 and Bcl-2 expression; on the other hand, we did not find a significant difference in the five-year overall survival with respect to Fas protein expression. Conclusion: We found that P53 and Bcl-2 protein expression had a negative effect on prognosis and survival in patients with primary gastrointestinal diffuse large B-cell lymphoma.
    [Show full text]
  • Paraneoplastic Cerebellar Degeneration Preceding the Diagnosis of Hodgkin’S Lymphoma
    CA s E r E p o r T paraneoplastic cerebellar degeneration preceding the diagnosis of hodgkin’s lymphoma P.F. Ypma1*, P.W. Wijermans1, H. Koppen2, P.A.E. Sillevis Smitt3 Departments of 1Haematology and Neurology, HagaZiekenhuis, location Leyenburg, Leyweg 75, 545 CH The Hague, the Netherlands, 3Department of Neurology, Erasmus Medical Centre, Dr Molewaterplein 40, 3015 GD Rotterdam, the Netherlands, *corresponding author: tel.: +31 (0)70-359 5 56, fax: +31 (0)70-359 22 09, e-mail: [email protected] A B s T r act i N T r o d u ct i o N paraneoplastic cerebellar degeneration (pCd) can present Paraneoplastic cerebellar degeneration (PCD) typically as a severe and (sub)acute cerebellar syndrome. pCd presents with (sub)acute, severe cerebellar ataxia.1 PCD can accompany different kinds of neoplasms including is most commonly associated with small cell lung cancer small cell lung cancer, adenocarcinoma of the breast and (SCLC), adenocarcinoma of the breast and ovary, followed ovary, and hodgkin’s lymphoma. A 34-year-old patient is by Hodgkin’s lymphoma.2 Sometimes the diagnosis described with acute dysarthria, gait ataxia and diplopia. of a malignant disease is made before the syndrome despite extensive laboratory and radiological evaluations in occurs. Usually, however, PCD precedes the underlying this patient with rapidly deteriorating cerebellar syndrome, neoplastic disease, posing a diagnostic challenge. The the diagnosis of a paraneoplastic syndrome was only detection of antineuronal autoantibodies directed against made after several months, when an anti-Tr antibody was onconeural antigens helps diagnose the neurological detected in his serum.
    [Show full text]
  • Plasma Circulating Tumor DNA Assessment Reveals KMT2D As A
    Li et al. Biomarker Research (2020) 8:27 https://doi.org/10.1186/s40364-020-00205-4 RESEARCH Open Access Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma Qiong Li1,2†, Wei Zhang1,2†, Jiali Li1,2, Jingkang Xiong1,2, Jia Liu1,2, Ting Chen1,2, Qin Wen1,2, Yunjing Zeng1,2, Li Gao1,2, Lei Gao1,2, Cheng Zhang1,2, Peiyan Kong1,2, Xiangui Peng1,2, Yao Liu1,2*, Xi Zhang1,2* and Jun Rao1,2* Abstract Background: The early detection of tumors upon initial diagnosis or during routine surveillance is important for improving survival outcomes. Here, we investigated the feasibility and clinical significance of circulating tumor DNA (ctDNA) detection for Extranodal NK/T-cell lymphoma, nasal type (ENTKL). Methods: The plasma ctDNA assessment was based on blood specimens collected from 65 newly diagnosed patients with ENKTL in the hematology medical center of Xinqiao Hospital. Longitudinal samples collected under chemotherapy were also included. The gene mutation spectrum of ENKTL was analyzed via next generation sequencing. Results: We found that the most frequently mutated genes were KMT2D (23.1%), APC (12.3%), ATM (10.8%), ASXL3 (9.2%), JAK3 (9.2%), SETD2 (9.2%), TP53 (9.2%) and NOTCH1 (7.7%). The mutation allele frequencies of ATM and JAK3 were significantly correlated with the disease stage, and mutated KMT2D, ASXL3 and JAK3 were positively correlated with the metabolic tumor burden of the patients. Compared with the tumor tissue, ctDNA profiling showed good concordance (93.75%). Serial ctDNA analysis showed that treatment with chemotherapy could decrease the number and mutation allele frequencies of the genes.
    [Show full text]
  • Cell-Free DNA As a Biomarker in Diffuse Large B-Cell Lymphoma A
    Critical Reviews in Oncology / Hematology 139 (2019) 7–15 Contents lists available at ScienceDirect Critical Reviews in Oncology / Hematology journal homepage: www.elsevier.com/locate/critrevonc Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review T ⁎ Javier Arzuaga-Mendeza,b,1, Endika Prieto-Fernándeza, ,1, Elixabet Lopez-Lopeza,c, Idoia Martin-Guerreroa,c, Juan Carlos García-Ruizb,c, Africa García-Orada,c a Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, 48940, Spain b Hematology and Hemotherapy Service, Cruces University Hospital, Barakaldo, Bizkaia, 48903, Spain c BioCruces Health Research Institute, Barakaldo, Bizkaia, 48903, Spain ARTICLE INFO ABSTRACT Keywords: Cell-free DNA (cfDNA), which is DNA released from cells into the circulation, is one of the most promising non- Diffuse Large B-Cell Lymphoma (DLBCL) invasive biomarkers in cancer. This approach could be of interest for the management of Diffuse Large B-Cell Non-Hodgkin lymphoma Lymphoma (DLBCL) patients, which is the most common non-Hodgkin lymphoma. Then, the aim of this sys- Liquid biopsy tematic review was to define the utility of cfDNA in this disease. Selected articles were classified in four groups, Cell-free DNA (cfDNA) depending on the aspects of cfDNA studied, i.e. concentration, methylation, IgH gene rearrangements, and so- Biomarker matic mutations. While concentration and methylation of cfDNA need to be further analyzed, IgH gene re- Treatment response arrangements and somatic mutations seem to be the most promising biomarkers to date. Their detection has been shown to allow disease monitoring and early prediction of relapse.
    [Show full text]
  • EHA-TSH Hematology Tutorial on Lymphoma
    EHA-TSH Hematology Tutorial on Lymphoma Hodgkin Lymphoma: Diagnosis and Treatment (First Line and Relapsed Disease Speaker: Pervin Topcuoglu İzmir, Turkey April 6-7, 2019 I have no actual or potential conflict of interest in relation to this presentation Learning Objectives ‒ the morphological and clinical features ‒ the staging work-up and apply the Lugano classification to patients with Hodgkin lymphoma. ‒ the risk stratification prior to the treatment ‒ the treatment in patients with newly diagnosed HL and in those with relapse/refractory HL Content ‒ History ‒ Definition ‒ Epidemiology ‒ Subtypes ‒ Etiology ‒ Presentation ‒ Diagnosis ‒ Management ‒ Follow-up ‒ Summary and Future History History Definition ‒ A type of malignant lymphoma ‒ Germinal B center or Post-GBC ‒ Dorothy Reed and Carl Sternberg first described the malignant cells of HL-called as Reed Sternberg cells -Owl Eyes appearance ‒ The first cancer could be successfully treated by radiation therapy and also combination with chemotherapy (ChT) Epidemiology Median age at 40% diagnosis 30% 39 20% New cases 2.4.-2.5/100,000 persons 10% (EU and US data) 0% male, 2.9; female, 2.2 Percent o Deathso Percent HL most frequently diagnosed in <20 >84 35-44 45-54 55-64 65-74 75-84 20-34 patients 20-34 yrs of age, older Age than 55 yrs of age Increased incidence in industrialized Median age at death countries 67 Nodular sclerosis subtype associated with high standard of living Hodgkin Lymphoma Cancer Stat Facts. 2018. https://seer.cancer.gov/statfacts/html/hodg.html. Epidemiology Estimated New Cases in 2018 8,500 % of All New Cancer Cases 0.5% Percent Surviving 5 years Estimated Death in 2018 1,050 86.6 % % of All Cancer Deaths 0.2 % 2008-2014 3,00 2,50 2,00 1,50 1,00 Persons 0,50 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 0,00 1992 Number Per 100,000 100,000 Per Number Years New Cases Death-US Hodgkin Lymphoma Cancer Stat Facts.
    [Show full text]
  • Tumour Related Prognostic Factors
    NATIONAL CANCER DATA DICTIONARY V 1.0 Part A BASIC VARIABLES for Adults, Adolescents, and Children 7.6.2019 CONTENTS CONTENTS ....................................................................................................................................... 1 ABBREVIATIONS .............................................................................................................................. 7 CASE DEFINITIONS .......................................................................................................................... 8 Person age at diagnosis ................................................................................................................... 8 Person resident status ..................................................................................................................... 8 No veto from patient ....................................................................................................................... 8 Reportable diagnosed neoplasms ................................................................................................... 8 PATIENT DATA ................................................................................................................................ 9 Family Name(s)* ............................................................................................................................ 10 First Name(s)* ................................................................................................................................ 11 Sex .................................................................................................................................................
    [Show full text]
  • Peripheral T-Cell Lymphoma Facts No
    Peripheral T-Cell Lymphoma Facts No. 25 in a series providing the latest information for patients, caregivers and healthcare professionals www.LLS.org • Information Specialist: 800.955.4572 Highlights Introduction Peripheral T-cell lymphomas (PTCLs) are uncommon and l Peripheral T-cell lymphomas (PTCLs) comprise a aggressive types of non-Hodgkin lymphoma (NHL) that diverse group of uncommon and aggressive diseases develop in mature white blood cells called “T cells” and in which the patient’s T cells become cancerous. T-cell “natural killer (NK) cells.” lymphomas account for between 10 percent and 15 percent of all non-Hodgkin lymphomas (NHLs). NHL is the name for many different types of cancer that l The World Health Organization (WHO) divides start in cells called “lymphocytes,” a type of white blood PTCLs into three categories (nodal, extranodal cell that helps the body fight infection. There are three and leukemic) and classified subtypes within these types of lymphocytes: B lymphocytes (B cells), categories of PTCLs. Getting an accurate diagnosis T lymphocytes (T cells) and natural killer cells (NK cells). and knowing your PTCL subtype is important. NHL may arise in B cells or T cells. B-cell lymphomas are more common than T-cell lymphomas. NHLs may be l PTCLs are rare in the United States and are more indolent (slow growing) or aggressive (fast growing). For common in Asia, Africa and the Caribbean, possibly more information about NHL, please see the free Leukemia due to exposure to specific viruses, such as the & Lymphoma Society (LLS) booklets Non-Hodgkin Epstein-Barr virus (EBV) and the human T-cell Lymphoma and The Lymphoma Guide – Information for leukemia virus-1 (HTLV-1).
    [Show full text]